JohnAnthonyGlaspyMD

Oncology • Los Angeles, CA

Professor of Medicine, UCLA

Join to view full profile

Dr. Glaspy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Glaspy's full profile

Already have an account?

Office
100 UCLA Medical Plaza
Suite 550
Los Angeles, CA 90095
Phone+1 310-481-9737

Fax+1 310-481-9737

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1979 - 1983
David Geffen School of Medicine at UCLAClass of 1979

Certifications & Licensure

OR State Medical License 1989 - Present
CA State Medical License 1980 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Top Doctors:Southern California Castle Connolly, 2012
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma Start of enrollment: 1997 Jul 01
Completed
Phase 1
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Start of enrollment: 2000 Apr 01
Completed
Phase 3
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
Completed
Phase 4
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Start of enrollment: 2002 Sep 01
Unknown status
Phase 3
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 Start of enrollment: 2003 Aug 01
Unknown status
Not Applicable
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Start of enrollment: 2003 Aug 01
Completed
Phase 3
Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma Start of enrollment: 2007 Jan 01
Completed
Phase 2
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 2
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Start of enrollment: 2009 Oct 13
Completed
Phase 2
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2016 Aug 01
Withdrawn
Not Applicable
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Start of enrollment: 2019 Jul 10
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

4863 citations
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma Taylor
Nature. 2014-11-27
18 citations
Can erythropoietin therapy improve survival
John A. Glaspy, Juergen Dunst
Oncology. 2004-10-01
11 citations
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Camille F Ng, John Glaspy, Veronica R Placencio-Hickok, Shant Thomassian, Jun Gong
Journal of the National Comprehensive Cancer Network. 2022-10-01

Abstracts/Posters

Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion...
John Glaspy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Insights Into Anemia in Chronic Kidney Disease and Beyond: New Discoveries, Strategies, and Models of Care
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Shop TalkFebruary 20th, 2021
Coronavirus Is Forcing Breast Cancer Patients to Make Tough DecisionsApril 12th, 2020
Stand up to Cancer Laura Ziskin Prize Awarded to Drs. Leisha A. Emens and Xiang ZhangJanuary 28th, 2020
Join now to see all

Grant Support

Resource For Minority Patient RecruitmentNational Cancer Institute2010–2011
Women'S CancersNational Cancer Institute2009–2011
Core--Clinical Trial Protocol Review And Monitoring SystemNational Cancer Institute1994–2002
Randomized Trial Of Peripheral Blood Progenitor Cell (PBPC) MobilizationNational Center For Research Resources1999–2001
Core--Clinical Material/ProtocolsNational Cancer Institute1995–2000
Randomized, Placebo-Controlled, Blinded, Phase I/II Trial Of Peg-RhumgdfNational Center For Research Resources1996–1997
Randomized Trial Of Peripheral Blood Progenitor Cell MobilizationNational Center For Research Resources1996–1997
Peripheral Blood Progenitor Cells Mobilized By F-Met-HuscfNational Center For Research Resources1995–1996

JohnAnthonyGlaspyMD

Dr. Glaspy is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.